Celera Genomics to Provide Database Subscription to Immunex Corporation.Business Editors and Medical Writers ROCKVILLE, Md., and SEATTLE--(BW HealthWire)--June 27, 2000 Celera Genomics (NYSE NYSE See: New York Stock Exchange : CRA See Community Reinvestment Act. ), a PE Corporation business, and Immunex Corporation (Nasdaq: IMNX) today announced that they have entered into a five-year comprehensive genomics agreement including a subscription to all of Celera's current database products. The database subscription for Immunex gives its researchers access to four databases developed by Celera until 2005. All four of Celera's databases include Celera proprietary information as well as publicly available data. First, the Celera Human Gene Index provides customers with the set of human genes derived from EST EST electroshock therapy. EST abbr. electroshock therapy sequencing programs. Second, Celera's Human Genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. Database is expected to provide the complete sequence of the human genome and the entire collection of human genes with links to associated biological and disease information. Third, the Drosophila Drosophila: see fruit fly. drosophila Any member of about 1,000 species in the dipteran genus Drosophila, commonly known as fruit flies but also called vinegar flies. Some species, particularly D. Genome Database provides the complete sequence of the Drosophila melanogaster genome sequence generated by Celera's whole genome shotgun sequencing In genetics, shotgun sequencing is a method used for sequencing long DNA strands. It is named by analogy with the rapidly-expanding, quasi-random firing pattern of a shotgun. strategy. The Drosophila genome database is extensively annotated with gene, protein and biological information. Fourth, the Mouse Genome Database being generated by Celera should allow for comparative analysis with the human genome that may be especially significant for the identification of genes and gene regulatory regions In biochemistry, a regulatory region is a DNA base sequence that controls gene expression. Overview A gene is a stretch of DNA that codes for the creation of a particular protein, such as an enzyme. of importance to understanding human biology Human biology is an interdisciplinary academic field of biology, biological anthropology, and medicine which focuses on humans; it is closely related to primate biology, and a number of other fields. . Access to the databases also provides Immunex with associated comprehensive bioinformatics systems and tools for viewing, browsing, and analyzing genomic information. "The subscription agreement between Immunex and Celera demonstrates the next step in realizing the significance of gene discovery," said J. Craig Venter  The introduction of this article is too short.To comply with Wikipedia's lead section guidelines, it should be expanded. , Ph.D., Celera's president and chief scientific officer. "It is important because it brings together the research and development resources at Immunex with Celera's unique ability to provide researchers with accurate human genome sequence, tools to identify and understand genes and regulatory functions, qualitative comparisons with other genomic sequences, and powerful bioinformatics capabilities." "Celera's genomic databases represent an important milestone in the sequencing of the human genome," said Doug Williams There are several people named Doug Williams, including:
PE Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. The PE Biosystems Group (NYSE: PEB PEB Physical Evaluation Board PEB Presidential Emergency Board PEB Post Exposure Bake PEB Professional Engineers Board (Singapore) PEB Pre-Engineered Building PEB Personal Electronic Ballot PEB Performance Evaluation Board ), headquartered in Foster City, CA and with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software, and contract related services to the life science industry and research community. Information about the company, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at http://www.pecorporation.com or by phoning (800) 762-6923. Immunex Corporation is a biopharmaceutical company dedicated to improving lives through immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. science innovations. American Home Products owns a majority interest in Immunex. AHP AHP Assistant House Physician. is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of prescription drugs, including biotechnological and vaccine products, animal health care products and over-the-counter medications. This release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , product commercialization and other risks described from time to time in the SEC reports filed by Immunex, including the most recently filed 10-K and 10-Q forms. For more information, please refer to www.immunex.com. Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "anticipate," "should," "intend," "planned," "estimated," and "potential," among others. These forward-looking statements are based on PE Corporation's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics' businesses include but are not limited to (1) operating losses to date; (2) a unique and developing business plan; (3) dependence on the timely completion of the sequencing and assembly of the human genome; (4) uncertainty of revenue growth; (5) unproven use of genomics information to develop products; (6) intense competition in the evolving genomics industry; (7) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (8) heavy reliance on strategic relationship with the PE Biosystems group; (9) potential product liability claims; (10) liabilities related to use of hazardous materials; (11) lengthy sales cycle; (12) dependence on the unique expertise of its scientific and management staff; (13) uncertainty of patent, copyright and intellectual property protection; (14) dependence on computer hardware, software, and internet applications; (15) access to biological materials; (16) legal, ethical and social issues affecting demand for products; (17) disruptions caused by rapid growth of the business; (18) government regulation of its products and services; (19) risks of future acquisitions; and (20) other factors that might be described from time to time in PE Corporation's filings with the Securities and Exchange Commission. Note to editors: Celera, Celera Genomics, and PE Biosystems are trademarks of PE Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion